BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23929266)

  • 1. Loss of androgen receptor expression predicts early recurrence in triple-negative and basal-like breast cancer.
    Thike AA; Yong-Zheng Chong L; Cheok PY; Li HH; Wai-Cheong Yip G; Huat Bay B; Tse GM; Iqbal J; Tan PH
    Mod Pathol; 2014 Mar; 27(3):352-60. PubMed ID: 23929266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Met and ERβ expression differences in basal-like and non-basal-like triple-negative breast cancer.
    Ren X; Yuan L; Shen S; Wu H; Lu J; Liang Z
    Tumour Biol; 2016 Aug; 37(8):11385-95. PubMed ID: 26968553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor expression is a favorable prognostic factor in triple-negative breast cancers.
    Zuo T; Wilson P; Cicek AF; Harigopal M
    Hum Pathol; 2018 Oct; 80():239-245. PubMed ID: 29902579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
    Thike AA; Tan PH; Ikeda M; Iqbal J
    Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer.
    Iqbal J; Thike AA; Cheok PY; Tse GM; Tan PH
    Histopathology; 2012 Oct; 61(4):652-9. PubMed ID: 22759273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong association of fascin expression with triple negative breast cancer and basal-like phenotype in African-American women.
    Esnakula AK; Ricks-Santi L; Kwagyan J; Kanaan YM; DeWitty RL; Wilson LL; Gold B; Frederick WA; Naab TJ
    J Clin Pathol; 2014 Feb; 67(2):153-60. PubMed ID: 23986556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of androgen receptor in inflammatory breast cancer and its clinical relevance.
    Gong Y; Wei W; Wu Y; Ueno NT; Huo L
    Cancer; 2014 Jun; 120(12):1775-9. PubMed ID: 24634055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic markers in triple-negative breast cancer.
    Rakha EA; El-Sayed ME; Green AR; Lee AH; Robertson JF; Ellis IO
    Cancer; 2007 Jan; 109(1):25-32. PubMed ID: 17146782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation.
    Niemeier LA; Dabbs DJ; Beriwal S; Striebel JM; Bhargava R
    Mod Pathol; 2010 Feb; 23(2):205-12. PubMed ID: 19898421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.
    Gazinska P; Grigoriadis A; Brown JP; Millis RR; Mera A; Gillett CE; Holmberg LH; Tutt AN; Pinder SE
    Mod Pathol; 2013 Jul; 26(7):955-66. PubMed ID: 23392436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stratification of Prognosis of Triple-Negative Breast Cancer Patients Using Combinatorial Biomarkers.
    Yue Y; Astvatsaturyan K; Cui X; Zhang X; Fraass B; Bose S
    PLoS One; 2016; 11(3):e0149661. PubMed ID: 26930401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma.
    Li JP; Zhang XM; Zhang Z; Zheng LH; Jindal S; Liu YJ
    Medicine (Baltimore); 2019 May; 98(18):e15449. PubMed ID: 31045815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer.
    Debeb BG; Gong Y; Atkinson RL; Sneige N; Huo L; Gonzalez-Angulo AM; Hung MC; Valero V; Ueno NT; Woodward WA
    J Exp Clin Cancer Res; 2014 Jul; 33(1):58. PubMed ID: 25051981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.
    Gasparini P; Fassan M; Cascione L; Guler G; Balci S; Irkkan C; Paisie C; Lovat F; Morrison C; Zhang J; Scarpa A; Croce CM; Shapiro CL; Huebner K
    PLoS One; 2014; 9(2):e88525. PubMed ID: 24505496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study.
    Zhou W; Jirström K; Johansson C; Amini RM; Blomqvist C; Agbaje O; Wärnberg F
    BMC Cancer; 2010 Nov; 10():653. PubMed ID: 21118480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular phenotypes of DCIS predict overall and invasive recurrence.
    Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
    Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
    Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.